<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940805-2-00144</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``Because of the relative novelty of the procedures that are used, the potentially irreversible consequences of the procedures performed, and the fact that many of the potential risks remain undefined, the Informed Consent document should include the following specific information in addition to any requirements of the DHHS regulations for the Protection of Human Subjects (45 CFR 46). Indicate if each of the specified items appears in the Informed Consent document or, if not included in the Informed Consent document, how those items will be presented to potential subjects. Include an explanation if any of the following items are omitted from the consent process or the Informed Consent document.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=73 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a. General Requirements of Human Subjects Research  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(1). Description/Purpose of the Study  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The subjects should be provided with a detailed explanation in non-technical language of the purpose of the study and the procedures associated with the conduct of the proposed study, including a description of the gene transfer component.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(2). Alternatives  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The Informed Consent document should indicate the availability of therapies  <!-- PJG 0012 frnewline --> and the possibility of other investigational interventions and approaches.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(3). Voluntary Participation  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The subjects should be informed that participation in the study is voluntary and that failure to participate in the study or withdrawal of consent will not result in any penalty or loss of benefits to which the subjects are otherwise entitled.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(4). Benefits  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The subjects should be provided with an accurate description of the possible benefits, if any, of participating in the proposed study. For studies that are not reasonably expected to provide a therapeutic benefit to subjects, the Informed Consent document should clearly state that no direct clinical benefit to subjects is expected to occur as a result of participation in the study, although knowledge may be gained that may benefit others.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(5). Possible Risks, Discomforts, and Side Effects  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``There should be clear itemization in the Informed Consent document of types of adverse experiences, their relative severity, and their expected frequencies. For consistency, the following definitions are suggested: side effects that are listed as mild should be ones which do not require a therapeutic intervention; moderate side effects require an intervention; and severe side effects are potentially fatal or life-threatening, disabling, or require prolonged hospitalization.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ``If verbal descriptors (e.g., `rare,' `uncommon,' or `frequent') are used to express quantitative information regarding risk, these terms should be explained.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ``The Informed Consent document should provide information regarding the  <!-- PJG 0012 frnewline --> approximate number of people who have previously received the genetic  <!-- PJG 0012 frnewline --> material under study. It is necessary to warn potential subjects that, for genetic materials previously used in relatively few or no humans, unforeseen risks are possible, including ones that could be severe.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ``The Informed Consent document should indicate any possible adverse medical consequences that may occur if the subjects withdraw from the study once the study has started.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(6). Costs  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The subjects should be provided with specific information about any financial costs associated with their participation in the protocol and in the long-term follow-up to the protocol that are not covered by the investigators or the institution involved.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            